Eli Lilly (LLY) Moves to Cut 340B Discounts for Non-Compliant Hospitals

Eli Lilly and Company (NYSE: LLY) plans to stop providing 340B discounted drug pricing to certain hospitals that have not met claims data reporting requirements introduced on February 1, according to reporting by Fierce Healthcare's Dave Muoio. The move marks an escalation in Lilly's enforcement of compliance standards tied to the federal 340B drug discount program. LLY fell 1.34% on Friday, June 12, 2026, closing at $1,145.37.

Key Details

• Lilly's action targets hospitals that failed to comply with claims data reporting requirements that took effect February 1.
• The decision to withhold 340B pricing is a direct enforcement mechanism, not a proposed policy change.
• The move has drawn opposition, per Fierce Healthcare's reporting, signaling potential pushback from affected hospital systems.
• Lilly is currently held by 132 hedge funds as of Q1 2026, reflecting broad institutional exposure to any policy or regulatory risk the action may create.

Investor Takeaway

Lilly's 340B enforcement push puts the company in direct conflict with hospital groups that rely on the discount program, a tension that could attract regulatory scrutiny. Analyst consensus remains at Strong Buy or Buy from 31 of 39 covering analysts as of June 1, 2026, suggesting the market views the compliance action as a manageable risk rather than a structural threat to the franchise.